Depression psychedelic and ketamine research trials
If you are thinking about suicide or are in crisis, please get help now. Call your local emergency number, or a crisis line: in the US call or text 988, in the UK and Ireland call Samaritans on 116 123, in Israel call ERAN on 1201. For other countries, search for findahelpline.com.
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
430 registered studies are counted for depression. By compound: 104 psilocybin, 8 LSD, 12 DMT, 6 5-MeO-DMT, 2 ayahuasca, 310 ketamine and 1 ibogaine. By registry status: 92 recruiting, 27 not yet recruiting, 6 enrolling by invitation, 31 active, not recruiting, 178 completed, 25 terminated, 3 suspended, 24 withdrawn and 44 status not reported. By phase: 16 early phase 1, 71 phase 1, 152 phase 2, 52 phase 3, 46 phase 4, 52 not applicable and 41 not reported. Reported start years run from 2004 (earliest) to 2027 (latest).
This page includes major depressive disorder, treatment-resistant depression, bipolar depression and postpartum depression when the title names depression. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 430 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 104 |
| LSD | 8 |
| DMT | 12 |
| 5-MeO-DMT | 6 |
| Ayahuasca | 2 |
| Ketamine | 310 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 92 | 21% |
| Not yet recruiting | 27 | 6% |
| Enrolling by invitation | 6 | 1% |
| Active, not recruiting | 31 | 7% |
| Completed | 178 | 41% |
| Terminated | 25 | 6% |
| Suspended | 3 | 1% |
| Withdrawn | 24 | 6% |
| Status not reported | 44 | 10% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 16 | 4% |
| Phase 1 | 71 | 17% |
| Phase 2 | 152 | 35% |
| Phase 3 | 52 | 12% |
| Phase 4 | 46 | 11% |
| Not applicable | 52 | 12% |
| Not reported | 41 | 10% |
Countries
Country is taken from the study's linked research site. 12 of 430 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 243 | 57% |
| Canada | 44 | 10% |
| France | 12 | 3% |
| United Kingdom | 12 | 3% |
| China | 11 | 3% |
| Brazil | 9 | 2% |
| Israel | 9 | 2% |
| Switzerland | 8 | 2% |
| Austria | 7 | 2% |
| Australia | 6 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 145 |
| 2020 to 2023 | 133 |
| 2015 to 2019 | 98 |
| 2010 to 2014 | 44 |
| Before 2010 | 9 |
| Start date not reported | 1 |
Study design
- 389 interventional and 40 observational studies.
- Median planned or actual enrolment is 45 participants (range 1 to 50,000, across 406 records that report it).
Registered studies
The 50 studies with the latest start dates, newest first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Group PACBT for Depression | NCT07566104 | Not yet recruiting | Phase 2 | 2027-01-01 | Psilocybin |
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response | NCT07768618 | Not yet recruiting | Phase 2 | 2026-12-01 | Ketamine |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | NCT07833761 | Not yet recruiting | Phase 1 | 2026-12-01 | Psilocybin |
| Oral and Sublingual Ketamine | NCT07683988 | Not yet recruiting | Phase 1 | 2026-10-01 | Ketamine |
| A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes | NCT07839338 | Not yet recruiting | Phase 3 | 2026-10-01 | Ketamine |
| Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | NCT07810023 | Enrolling by invitation | Not applicable | 2026-09-10 | Ketamine |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | NCT07801703 | Not yet recruiting | Phase 2 | 2026-09-01 | Ketamine |
| Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | NCT07824973 | Not yet recruiting | Not applicable | 2026-09-01 | Ketamine |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | Psilocybin |
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | NCT07716098 | Recruiting | Phase 3 | 2026-08-03 | Ketamine |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | NCT07499583 | Not yet recruiting | Phase 1 | 2026-08-01 | Psilocybin |
| Inhaled DMT for Major Depressive Disorder | NCT07562191 | Recruiting | Phase 2 | 2026-08-01 | DMT |
| Anesthesia-Masked Psilocybin Therapy for Major Depression | NCT07479550 | Not yet recruiting | Phase 2 | 2026-07-01 | Psilocybin |
| Shortened LSD Intervention for Major Depressive Disorder | NCT07503002 | Not yet recruiting | Phase 1 | 2026-07-01 | LSD |
| Biomarker-Guided Antidepressant Selection | NCT07680140 | Recruiting | Phase 4 | 2026-07-01 | Ketamine |
| Biomarker Discovery for Suicide Precision Circuit Therapeutics | NCT07723066 | Not yet recruiting | Not reported | 2026-07-01 | Ketamine |
| Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | NCT07737990 | Enrolling by invitation | Not applicable | 2026-07-01 | Psilocybin |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | NCT07226232 | Recruiting | Phase 3 | 2026-06-01 | Psilocybin |
| Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | NCT07565909 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | Ketamine |
| Psilocybin-Assisted Therapy as a Treatment for Depression | NCT07582120 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | NCT07638553 | Recruiting | Phase 3 | 2026-06-01 | Psilocybin |
| Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder | NCT07602153 | Not yet recruiting | Not reported | 2026-05-30 | Ketamine |
| Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | NCT07639359 | Recruiting | Phase 2 | 2026-05-14 | Ketamine |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | NCT06781697 | Recruiting | Phase 3 | 2026-05-01 | Ketamine |
| Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy | NCT07373535 | Not yet recruiting | Phase 2 | 2026-05-01 | Psilocybin |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | NCT07610369 | Recruiting | Phase 2 | 2026-05-01 | Psilocybin |
| Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression | NCT07211438 | Recruiting | Phase 2 | 2026-04-01 | Psilocybin |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | NCT07336238 | Active, not recruiting | Phase 2 | 2026-04-01 | Psilocybin |
| Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | NCT07563868 | Recruiting | Not applicable | 2026-04-01 | Ketamine |
| Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | NCT07703722 | Recruiting | Phase 3 | 2026-04-01 | Psilocybin |
| ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 | NCT07528014 | Recruiting | Not reported | 2026-03-25 | Ketamine |
| A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression | NCT07396272 | Active, not recruiting | Phase 2 | 2026-03-01 | Ketamine |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder | NCT07405606 | Not yet recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | NCT06788249 | Recruiting | Early Phase 1 | 2026-02-01 | Ketamine |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | 2026-02-01 | Ketamine |
| Esketamine With or Without Integration Therapy for Treatment-Resistant Depression | NCT07369102 | Recruiting | Phase 4 | 2026-02-01 | Ketamine |
| Mitochondrial Function After Ketamine | NCT07399756 | Not yet recruiting | Not reported | 2026-02-01 | Ketamine |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | NCT07227454 | Recruiting | Phase 3 | 2026-01-08 | Ketamine |
| RCT of Psilocybin-assisted CBT for Depression | NCT07281352 | Recruiting | Phase 1 | 2026-01-05 | Psilocybin |
| Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer | NCT07216404 | Recruiting | Phase 2 | 2026-01-01 | Psilocybin |
| Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression | NCT07247006 | Not yet recruiting | Phase 2 | 2026-01-01 | Ketamine |
| Psilocybin to Treat Depression in Spinal Cord Injury | NCT07251491 | Recruiting | Phase 1 | 2026-01-01 | Psilocybin |
| Ketamine Biomarker Validation | NCT07307768 | Not yet recruiting | Phase 1 | 2025-12-20 | Ketamine |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | 2025-12-10 | Psilocybin |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) | NCT07247370 | Not yet recruiting | Phase 1 | 2025-12-10 | Ketamine |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression | NCT06419439 | Recruiting | Phase 2 | 2025-12-03 | Ketamine |
| Imaging Depression in Parkinson's Disease | NCT06402955 | Recruiting | Phase 2 | 2025-12-01 | Ketamine |
| Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | NCT07183748 | Recruiting | Phase 2 | 2025-12-01 | Psilocybin |
| Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | NCT07247968 | Recruiting | Early Phase 1 | 2025-11-25 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Other condition hubs
Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk